Abstract
IntroductionCommercial assays for monitoring Infliximab (IFX) and anti-drug antibodies (ADAb) are currently available. The heterogeneity of these assays and lack of standardisation of ADAb may cause difficulties in interpretation, in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have